Status:
COMPLETED
A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults
Lead Sponsor:
Assembly Biosciences
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study is designed to assess the relative bioavailability of ABI-H2158 tablets (Test Formulation) compared to ABI-H2158 tablets (Reference Formulation). The effect of food on the pharmacokinetics ...
Eligibility Criteria
Inclusion
- 1\. No clinically significant abnormal findings on physical exam, medical history, or clinical laboratory results at screening.
Exclusion
- Positive test results for human immunodeficiency virus (HIV) or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Key Trial Info
Start Date :
September 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 7 2019
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04083716
Start Date
September 6 2019
End Date
October 7 2019
Last Update
November 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion
Tempe, Arizona, United States, 85283